Moderna swings to Q3 net income of $162 million; Q3 revenue rises 29% year over year to $1.31 billion

Bitget2026/11/06 11:47

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Moderna swung to a third-quarter 2026 net profit of $162 million from a year-earlier loss.
Revenue climbed 29% year-over-year to $1.31 billion, driven primarily by higher international COVID vaccine sales.
Research and development expenses fell 27% year-over-year to $583 million, primarily due to lower clinical development costs.
Intismeran combined with KEYTRUDA reduced recurrence or death risk by 42% versus KEYTRUDA alone in a Phase 3 melanoma study.
The 2026 revenue growth outlook rose to 15%-25% from up to 10% previously.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611060645ACCESSWRNAPR_____1247635) on November 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Moderna swings to Q3 net income of $162 million; Q3 revenue rises 29% year over year to $1.31 billion

You may also like

Crypto prices